SORRENTO THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0113 USD | -22.07% |
|
+7.62% | -90.85% |
| Apr. 10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
| Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Financials (USD)
| Sales 2021 | 52.9M | Sales 2022 | 62.84M | Capitalization | 411M |
|---|---|---|---|---|---|
| Net income 2021 | -428M | Net income 2022 | -573M | EV / Sales 2021 | 29.1 x |
| Net Debt 2021 | 111M | Net Debt 2022 | 84.53M | EV / Sales 2022 | 7.89 x |
| P/E ratio 2021 |
-3.2
x | P/E ratio 2022 |
-0.65
x | Employees | 949 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.77% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -22.07% | ||
| 1 week | +7.62% | ||
| 1 month | -29.38% | ||
| 3 months | -58.15% | ||
| 6 months | -74.89% | ||
| Current year | -90.85% |
1 week
0.01
0.02
1 month
0.000.03
Current year
0.000.14
1 year
0.000.42
3 years
0.0011.07
5 years
0.0019.39
10 years
0.0026.80
| Managers | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 88-12-31 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 14-03-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 12-03-31 |
David Lemus
BRD | Director/Board Member | 61 | 17-09-30 |
Jaisim Shah
BRD | Director/Board Member | 63 | 13-09-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 1,487 M€ | +7.77% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 0.0113 | -22.07% | 49,497 |
| 24-05-30 | 0.0145 | +31.82% | 34,060 |
| 24-05-29 | 0.011 | +10.00% | 317,179 |
| 24-05-28 | 0.01 | -4.76% | 42,407 |
| 24-05-24 | 0.0105 | +16.67% | 23,572 |
End-of-day quote OTC Markets, May 30, 2024
More quotes
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Companyâs segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Companyâs immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
| 1st Jan change | Capi. | |
|---|---|---|
| -90.85% | 6.14M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- SRNE Stock
